Biocon Lines Up Rs 4,500-Crore Fund Raise via QIP

Biocon has appointed Kotak Mahindra Capital, Morgan Stanley, JP Morgan and HSBC Securities for a Rs 4,500-crore capital raise, likely through QIP by January 2026. Proceeds will fund the integration of Biocon Biologics and acquisition of Mylan’s residual stake.